Atopic Dermatitis

Lebrikizumab (Ebglyss; Eli and Lilly Company) is a monthly maintenance injection with proven efficacy in adults and children aged 12 to 18 years.

In July 2024, the FDA approved the supplemental new drug application for roflumilast cream 0.15% for patients 6 years and older.

Nemolizumab is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, which drives disease mechanisms in prurigo nodularis.

The Lancet published data from DELTA 1 and DELTA 2 trials that displayed treatment success among individuals treated with delgocitinib cream.

Roflumilast is approved as a once daily and steroid-free cream for rapid disease clearance and significant reduction in itch and for long-term disease control.

When initiated at a 15 mg dose and escalated to 30 mg, upadacitinib showed superiority compared with dupilumab, achieving Eczema Area and Severity Score (EASI) 90 at week 16.

Secondhand exposure to e-cigarette smoke may increase risk of pediatric atopic dermatitis in children.

The autoinjector will provide another option for adults in addition to the prefilled syringe that is currently available.

Parents and caregivers sometimes have concerns about their children receiving these injections, but researchers and experts assure that the FDA-approved biologic is safe and effective in young populations.

Corticophobia is defined as a phobia of topical corticosteroids due to negative feelings or beliefs, which can come from misinformation about the long-term effects.

The acceptance is based on positive data from the phase 3 ADORING 1 and ADORING 2 pivotal trials, as well as interim results from the phase 3 ADORING 3 open-label, long-term extension trial.

The efficacy data are consistent with other phase 3 studies, reinforcing lebrikizumab's potential as a first-line treatment across a range of skin tones.

Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

Topical niacinamide stabilizes the skin's outer barrier, reducing water loss and improving moisture levels in the epidermis.

Treating older patients requires a greater focus on treating their AD without exacerbating their comorbidities.

It's key for clinicians to optimize therapy prior to systemic agents.

A supplemental New Drug Application will be submitted for roflumilast cream 0.05% for the treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.

Acne, atopic dermatitis, rosacea, urticaria, and sunburn present differently and require specific management.

The treatment improved lung function at 12 weeks and quality of life at 4 weeks.

Clearer skin on the face and hands lasted 1 year into treatment.

Pharmacists play key roles in navigating prior authorizations and other limits on utilization, as well as educating and listening to patients and caregivers.

The primary outcome of the study includes an IGA score of 0 or 1, which indicated clear or almost clear skin, respectively, with a reduction, from baseline to week 16.

Expanded indication for abrocitinib (Cibinqo; Pfizer Inc) includes patients 12 to <18 years of age with refractory, moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic medications.

Greater prevalence of hand eczema among health care professionals working in COVID-19 units linked to increased hand sanitation habits.

Clinical trials show that patients with atopic dermatitis experienced improved symptoms with dupilumab starting at 8 weeks, with maximum effect around 12 weeks.

All primary and ranked secondary endpoints of the study were met at week 16, which were sustained or improved through week 24 and were coupled with patient-reported improvements compared with placebo in treating psoriatic arthritis.

The goals of therapy for atopic dermatitis include reducing symptoms of pruritis and dermatitis with disease control and prevention of flares.

ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.

Researchers discovered that a common anti-inflammatory drug could lower the number of patients on ventilators from COVID-19, increasing the likelihood of survival by more than 50%.

Guidelines provide information on the management and treatment of this common skin condition.